Quoin Pharmaceuticals(QNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

QNRX Quoin Pharmaceuticals

Not Yet Opened 08-10 16:00:00 EDT

5.36

+0.57

+11.90%

盘后5.36

+0.000.00%

19:55 EDT

High5.36	Low4.66	Vol22.86K
Open4.84	D1 Closing4.79	Amplitude14.72%
Mkt Cap10.77M	Tradable Cap8.74M	Total Shares2.01M
T/O114.07K	T/O Rate1.40%	Tradable Shares1.63M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"QNRX","market":"US","secType":"STK","nameCN":"Quoin Pharmaceuticals","latestPrice":5.36,"timestamp":1786392000000,"preClose":4.79,"halted":0,"volume":22857,"hourTrading":{"tag":"盘后","latestPrice":5.36,"preClose":5.36,"latestTime":"19:55 EDT","volume":420,"amount":2172.8074,"timestamp":1786406135920,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.11899791231732783,"floatShares":1629700,"shares":2008400,"eps":-10.427843,"marketStatus":"Not Yet Opened","change":0.57,"latestTime":"08-10 16:00:00 EDT","open":4.84,"high":5.36,"low":4.655,"amount":114070.075629,"amplitude":0.147182,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-10.427843,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1786435200000},"marketStatusCode":0,"adr":0,"adrRate":35,"exchange":"NASDAQ","adjPreClose":4.79,"preHourTrading":{"tag":"盘前","latestPrice":4.7,"preClose":4.79,"latestTime":"09:28 EDT","volume":243,"amount":1110.9699990000001,"timestamp":1786368488799,"change":-0.09,"changeRate":-0.018789,"amplitude":0.052192},"postHourTrading":{"tag":"盘后","latestPrice":5.36,"preClose":5.36,"latestTime":"19:55 EDT","volume":420,"amount":2172.8074,"timestamp":1786406135920,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.409899},"requestUrl":"/m/hq/s/QNRX/tweets","defaultTab":"tweets","newsList":[{"id":"2657459856","title":"Quoin Pharmaceuticals Updates Financial Calendar, Sets Q2 Results Release and Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657459856","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657459856?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:30","pubTimestamp":1786105816,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals updates financial calendar, sets Q2 results release and corporate updateQuoin Pharmaceuticals will release second-quarter 2026 financial results before the market opens on Aug. 1","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL7sffxY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4588","IE00BN0W2W23.USD","NDAQ","BCDF","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","LU2095319765.USD","LU0314104364.USD","QNRX","IE00BN0W2V16.EUR","SG9999014005.SGD","SG9999014039.USD","SG9999014021.USD","LU2210150020.SGD","BK4139","LU2210149790.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4112","IE00BKPKM429.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656537233","title":"Quoin Pharmaceuticals Ltd Expected to Post a Loss of $1.61 a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2656537233","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656537233?lang=en_us&edition=fundamental","pubTime":"2026-08-03 21:53","pubTimestamp":1785765184,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals Ltd <QNRX.OQ> expected to post a loss of $1.61 a share - Earnings PreviewQuoin Pharmaceuticals LtdQNRX.OQ,QNRX.Ois expected to  show no change in quarterly revenue when it report","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL8N4401J9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651804449","title":"Insider Traders Lose US$65k As Quoin Pharmaceuticals Drops","url":"https://stock-news.laohu8.com/highlight/detail?id=2651804449","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651804449?lang=en_us&edition=fundamental","pubTime":"2026-07-16 19:12","pubTimestamp":1784200359,"startTime":"0","endTime":"0","summary":"Insiders who acquired US$128.6k worth of Quoin Pharmaceuticals, Ltd.'s ( NASDAQ:QNRX ) stock at an average price of...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qnrx/quoin-pharmaceuticals/news/insider-traders-lose-us65k-as-quoin-pharmaceuticals-drops","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qnrx/quoin-pharmaceuticals/news/insider-traders-lose-us65k-as-quoin-pharmaceuticals-drops","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","QNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650213925","title":"Maxim Group Remains a Buy on Quoin Pharmaceuticals (QNRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2650213925","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650213925?lang=en_us&edition=fundamental","pubTime":"2026-07-10 23:55","pubTimestamp":1783698921,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Quoin Pharmaceuticals, with a price target of $16.00. Rahman...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maxim-group-remains-a-buy-on-quoin-pharmaceuticals-qnrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maxim-group-remains-a-buy-on-quoin-pharmaceuticals-qnrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","QNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650922495","title":"Quoin Pharmaceuticals announces FDA clearance of QRX003 IND application","url":"https://stock-news.laohu8.com/highlight/detail?id=2650922495","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650922495?lang=en_us&edition=fundamental","pubTime":"2026-07-09 21:16","pubTimestamp":1783602970,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals (QNRX) announced that the FDA has cleared the company’s investigational new drug, or IND, application for QRX003 for the trea...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-announces-fda-clearance-of-qrx003-ind-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-announces-fda-clearance-of-qrx003-ind-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LABU","BK4588","IND","QNRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650878924","title":"Quoin Pharma Wins FDA IND Clearance for Qrx003 in Peeling Skin Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2650878924","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650878924?lang=en_us&edition=fundamental","pubTime":"2026-07-09 20:34","pubTimestamp":1783600467,"startTime":"0","endTime":"0","summary":"Quoin Pharma wins FDA IND clearance for QRX003 in peeling skin syndromeQuoin Pharmaceuticals won FDA IND clearance for QRX003 in Peeling Skin Syndrome, enabling a Phase 2 trial planned for 2H 2026.The","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nNDL70vcql:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649674643","title":"Quoin Pharmaceuticals Announces Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2649674643","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649674643?lang=en_us&edition=fundamental","pubTime":"2026-07-07 05:22","pubTimestamp":1783372955,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals announces annual shareholder meetingQuoin Pharmaceuticals will hold its annual general meeting in Philadelphia on Aug. 20, 2026.Shareholders will vote on the election of seven di","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDL1zkNqD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647559338","title":"Quoin Pharmaceuticals receives notice of allowance for QRX003 patent","url":"https://stock-news.laohu8.com/highlight/detail?id=2647559338","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647559338?lang=en_us&edition=fundamental","pubTime":"2026-06-30 21:00","pubTimestamp":1782824412,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals (QNRX) announced that the United States Patent and Trademark Office, or USPTO, has issued a notice of allowance for U.S. Pate...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-receives-notice-of-allowance-for-qrx003-patent-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-receives-notice-of-allowance-for-qrx003-patent-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","QNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647555681","title":"Quoin Pharma Wins US Notice of Allowance for Netherton Syndrome Combination-treatment Patent Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2647555681","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647555681?lang=en_us&edition=fundamental","pubTime":"2026-06-30 20:35","pubTimestamp":1782822938,"startTime":"0","endTime":"0","summary":"Quoin Pharma wins US notice of allowance for Netherton syndrome combination-treatment patent applicationQuoin Pharmaceuticals received a USPTO Notice of Allowance for U.S. patent application 18/428,570 covering combination treatment for Netherton Syndrome.Claims cover treating Netherton Syndrome with topical serine protease inhibitor dipalmitoyl hydroxyproline plus an anti-inflammatory agent, including SPINK5 mutation patients.Patent is expected to issue following payment of the USPTO issue fee, supporting IP protection for investigational QRX003 .Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief on June 30, 2026, and is solely responsible for the i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL92TJYN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645113816","title":"NASDAQ Trade Halt Volatility Trading Pause at 09:57 Am","url":"https://stock-news.laohu8.com/highlight/detail?id=2645113816","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645113816?lang=en_us&edition=fundamental","pubTime":"2026-06-24 21:57","pubTimestamp":1782309457,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTVOLATILITY TRADING PAUSE AT 09:57 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nAQN2M4ZSJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645875837","title":"Quoin Pharmaceuticals Ltd : Maxim Group Cuts Target Price to $16 From $40","url":"https://stock-news.laohu8.com/highlight/detail?id=2645875837","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645875837?lang=en_us&edition=fundamental","pubTime":"2026-06-23 22:46","pubTimestamp":1782226016,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nFWN42V0LY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","QNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645983941","title":"Quoin Pharmaceuticals' Potential Skin Disease Treatment Receives US Name Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2645983941","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645983941?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:58","pubTimestamp":1782219516,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals'  investigational candidate for the treatment of Netherton Syndrome has received US Food and Drug Administration conditional approval to use the brand name Qyleki for QRX003, the company said Tuesday.The FDA has also granted the drug fast track and rare pediatric disease designations, and a phase 3 study is expected to begin in H2 2026, the company said.Quoin expects to file a potential new drug application in 2027, the company said.Netherton Syndrome is a rare, inherited skin ailment caused by a gene mutation and can lead to severe skin dysfunctions.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["QNRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645364248","title":"Quoin says FDA conditionally approves QYLEKI as brand name for QRX003 Netherton syndrome drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2645364248","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645364248?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:31","pubTimestamp":1782217919,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals secured FDA conditional clearance of QYLEKI as the proposed brand name for QRX003 in Netherton syndrome.The name will undergo final FDA proprietary review as part of a planned NDA filing targeted for 2027.Quoin expects to start a pivotal Phase 3 trial in the second half of 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL2MM0C1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","LU2210149790.SGD","IE00B64PRP62.GBP","BK4139","SG9999014005.SGD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","BK4585","NDAQ","LU2095319765.USD","LU2210150020.SGD","SG9999014013.SGD","IE00BN0W2V16.EUR","QNRX","SG9999014039.USD","SG9999014021.USD","BK4112","BK4588","IE00BN0W2W23.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644086923","title":"Quoin Pharmaceuticals Completes Establishment Of Japanese Subsidiary To Advance Commercial Readiness For Qrx003","url":"https://stock-news.laohu8.com/highlight/detail?id=2644086923","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644086923?lang=en_us&edition=fundamental","pubTime":"2026-06-18 21:07","pubTimestamp":1781788069,"startTime":"0","endTime":"0","summary":"June 18 (Reuters) - Quoin Pharmaceuticals Ltd <2EB0y.F>::*QUOIN PHARMACEUTICALS COMPLETES ESTABLISHMENT OF JAPANESE SUBSIDIARY TO ADVANCE COMMERCIAL READINESS FOR QRX003*QUOIN PHARMACEUTICALS - TO INI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nRSD7YHktZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644823085","title":"Quoin Pharmaceuticals establishes Japan subsidiary to support QRX003 commercialization plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2644823085","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644823085?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:31","pubTimestamp":1781785861,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals completed the establishment of a wholly owned subsidiary in Japan to support a planned direct launch of QRX003.Move strengthens commercial readiness in a core market following Japanese orphan-drug designation for QRX003 in Netherton syndrome.Japan subsidiary adds to a self-commercialization strategy in the US and Western Europe; partnerships cover 61 countries outside core territories.QRX003 is in Phase 2 whole-body trials; a pivotal Phase 3 study is slated for 2H 2026 with a potential NDA filing in 2027.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL5cvBjH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BKPKM429.USD","BK4585","LU2095319765.USD","IE00B3QW5Z07.USD","BK4112","IE00B64PRP62.GBP","NDAQ","IE00BN0W2W23.USD","LU0314104364.USD","QNRX","LU2210149790.SGD","SG9999014021.USD","IE00BN0W2V16.EUR","LU2210150020.SGD","BK4588","BK4139","SG9999014013.SGD","SG9999014005.SGD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643142750","title":"Quoin reports positive pediatric data in Netherton Syndrome program","url":"https://stock-news.laohu8.com/highlight/detail?id=2643142750","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643142750?lang=en_us&edition=fundamental","pubTime":"2026-06-16 21:18","pubTimestamp":1781615915,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals (QNRX) announced a positive clinical update from its ongoing pediatric Netherton Syndrome Compassionate Use program evaluatin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quoin-reports-positive-pediatric-data-in-netherton-syndrome-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quoin-reports-positive-pediatric-data-in-netherton-syndrome-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QNRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643275247","title":"Quoin says QRX003 improves 4 of 6 pediatric Netherton syndrome patients in compassionate use program","url":"https://stock-news.laohu8.com/highlight/detail?id=2643275247","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643275247?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:31","pubTimestamp":1781613104,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals reported a positive interim update from its pediatric compassionate-use program for QRX003 in Netherton syndrome.Most enrolled children were assessed as improved versus baseline across key clinical endpoints, supporting the drug’s potential in a core patient group.No treatment-related adverse events were reported in the cohort to date.A broader clinical data release, including results from ongoing Phase 2 studies, is scheduled for the coming months.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDLSxMCJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU0314104364.USD","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","BK4112","SG9999014005.SGD","IE00B3QW5Z07.USD","BK4585","BK4588","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU2210149790.SGD","LU2095319765.USD","BK4139","SG9999014021.USD","LU2210150020.SGD","QNRX","NDAQ","SG9999014039.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643527577","title":"Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2643527577","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643527577?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:30","pubTimestamp":1781613000,"startTime":"0","endTime":"0","summary":"Four of Six Patients Participating in the Compassionate Use Program Were Classified as‘Improved’ or ‘Significantly Improved’ from Baseline Assessment Across Key Clinical Endpoints All Six Patients Are","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/16/3312590/0/en/Quoin-Pharmaceuticals-Announces-Positive-Clinical-Update-from-Ongoing-Pediatric-Netherton-Syndrome-Compassionate-Use-Program.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNRX","IGA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640615042","title":"Quoin Pharmaceuticals' Skin Disorder Drug Receives Orphan Drug Designation in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2640615042","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640615042?lang=en_us&edition=fundamental","pubTime":"2026-06-04 21:03","pubTimestamp":1780578200,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals  said Thursday that Japan's Ministry of Health, Labour and Welfare has granted orphan drug designation to its experimental drug, QRX003, for the treatment of Netherton Syndrome.The company said the designation provides development incentives such as regulatory support, reduced fees, priority review, tax benefits, and up to 10 years of market exclusivity if approved.QRX003 is currently being evaluated in mid-stage studies, with a pivotal late-stage trial expected to begin in H2, Quoin said, adding that a US regulatory filing could follow next year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","QNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640615745","title":"Quoin says Japan MHLW grants orphan drug status to QRX003 for Netherton syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2640615745","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640615745?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:32","pubTimestamp":1780576379,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals said Japan’s MHLW granted orphan drug designation for QRX003 to treat Netherton syndrome.Designation offers development incentives in Japan, including up to 10 years of market exclusivity on approval.Phase 3 trial expected to start in H2 2026; NDA filing targeted for 2027.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL7WzhZk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BKPKM429.USD","BK4585","LU2095319765.USD","IE00B3QW5Z07.USD","BK4112","IE00B64PRP62.GBP","NDAQ","IE00BN0W2W23.USD","LU0314104364.USD","QNRX","LU2210149790.SGD","SG9999014021.USD","IE00BN0W2V16.EUR","LU2210150020.SGD","BK4588","BK4139","SG9999014013.SGD","SG9999014005.SGD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.quoinpharma.com","stockEarnings":[{"period":"1week","weight":0.2045},{"period":"1month","weight":0.2045},{"period":"3month","weight":-0.117},{"period":"6month","weight":-0.3317},{"period":"1year","weight":-0.2503},{"period":"ytd","weight":-0.6286}],"compareEarnings":[{"period":"1week","weight":0.0203},{"period":"1month","weight":0.0239},{"period":"3month","weight":0.0472},{"period":"6month","weight":0.1172},{"period":"1year","weight":0.2132},{"period":"ytd","weight":0.1336}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. operates as a subsidiary of Skinvisible, Inc.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.264124},{"month":2,"riseRate":0.2,"avgChangeRate":-0.199382},{"month":3,"riseRate":0.2,"avgChangeRate":-0.222445},{"month":4,"riseRate":0.2,"avgChangeRate":-0.15112},{"month":5,"riseRate":0.4,"avgChangeRate":-0.043514},{"month":6,"riseRate":0.4,"avgChangeRate":-0.066019},{"month":7,"riseRate":0.4,"avgChangeRate":-0.043305},{"month":8,"riseRate":0.6,"avgChangeRate":-0.03758},{"month":9,"riseRate":0,"avgChangeRate":-0.208503},{"month":10,"riseRate":0.5,"avgChangeRate":0.22434},{"month":11,"riseRate":0.4,"avgChangeRate":0.035616},{"month":12,"riseRate":0.2,"avgChangeRate":-0.187047}],"exchange":"NASDAQ","name":"Quoin Pharmaceuticals","nameEN":"Quoin Pharmaceuticals","securityTypeName":"DR","adrRate":"1:35"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Quoin Pharmaceuticals(QNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Quoin Pharmaceuticals(QNRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Quoin Pharmaceuticals,QNRX,Quoin Pharmaceuticals股票,Quoin Pharmaceuticals股票老虎,Quoin Pharmaceuticals股票老虎国际,Quoin Pharmaceuticals行情,Quoin Pharmaceuticals股票行情,Quoin Pharmaceuticals股价,Quoin Pharmaceuticals股市,Quoin Pharmaceuticals股票价格,Quoin Pharmaceuticals股票交易,Quoin Pharmaceuticals股票购买,Quoin Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Quoin Pharmaceuticals(QNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Quoin Pharmaceuticals(QNRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction